Related references
Note: Only part of the references are listed.Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis
Sabrina Paganoni et al.
MUSCLE & NERVE (2021)
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial OfReldesemtivIn Patients With ALS
Jeremy M. Shefner et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2021)
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis A Randomized Clinical Trial
Brian J. Wainger et al.
JAMA NEUROLOGY (2021)
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
Jesus S. Mora et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2020)
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis
Suma Babu et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2020)
Early focality and spread of cortical dysfunction in amyotrophic lateral sclerosis: A regional study across the motor cortices
Thanuja Dharmadasa et al.
CLINICAL NEUROPHYSIOLOGY (2020)
The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis
William Huynh et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)
Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis
Michael Swash et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study) Study protocol clinical trial (SPIRIT Compliant)
Steve Vucic et al.
MEDICINE (2020)
ALS is a multistep process in South Korean, Japanese, and Australian patients
Steve Vucic et al.
NEUROLOGY (2020)
A proposal for new diagnostic criteria for ALSY
Jeremy M. Shefner et al.
CLINICAL NEUROPHYSIOLOGY (2020)
Tamoxifen for amyotrophic lateral sclerosis A randomized double-blind clinical trial
Po-Chih Chen et al.
MEDICINE (2020)
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial
William Camu et al.
EBIOMEDICINE (2020)
The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis
Christian Lunetta et al.
JOURNAL OF NEUROLOGY (2020)
Great expectations: virus-mediated gene therapy in neurological disorders
Didu Kariyawasam et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
Christian Mueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Timothy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis
Sabrina Paganoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis
Robert D. Henderson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial
Jeffrey M. Statland et al.
MUSCLE & NERVE (2019)
Challenges with Novel Clinical Trial Designs: Master Protocols
Michael Cecchini et al.
CLINICAL CANCER RESEARCH (2019)
Validation of the revised classification of cognitive and behavioural impairment in ALS
Barbara Iazzolino et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis
Roisin McMackin et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
Leonard H. van den Berg et al.
NEUROLOGY (2019)
Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
Maria Pia Sormani et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
Ammar Al-Chalabi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Amyotrophic lateral sclerosis: Origins traced to impaired balance between neural excitation and inhibition in the neonatal period
Matthew C. Kiernan et al.
MUSCLE & NERVE (2019)
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial
Julian Gold et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2019)
Therapeutic Oligonucleotides: State of the Art
C. I. Edvard Smith et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 59 (2019)
Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
Ryuji Kaji et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Medical conferences: value for money?
Michael Swash et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis
Federico Verde et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial
R. S. Bedlack et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2019)
ALS longitudinal studies with frequent data collection at home: study design and baseline data
Seward B. Rutkove et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2019)
Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
Ruben P. A. van Eijk et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker
Jan Kassubek et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis
Maxim De Schaepdryver et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
Ton Fang et al.
LANCET NEUROLOGY (2018)
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial
Albert C. Ludolph et al.
LANCET NEUROLOGY (2018)
Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial
Bjorn Oskarsson et al.
MUSCLE & NERVE (2018)
Advances in therapy for spinal muscular atrophy: promises and challenges
Ewout J. N. Groen et al.
NATURE REVIEWS NEUROLOGY (2018)
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS
Michael Benatar et al.
NEUROLOGY (2018)
TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole
Moritz Oberstadt et al.
SCIENTIFIC REPORTS (2018)
Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis A Study of Humans and a Transgenic Mouse Model
Rebecca K. Sheean et al.
JAMA NEUROLOGY (2018)
Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS
Stephen A. Goutman et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
Christopher Crockford et al.
NEUROLOGY (2018)
Psychiatric disorders in C9orf72 kindreds Study of 1,414 family members
Emma M. Devenney et al.
NEUROLOGY (2018)
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Leonela Amoasii et al.
SCIENCE (2018)
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
Peter Connick et al.
BMJ OPEN (2018)
Master protocol trials in oncology: Review and new trial designs
Akihiro Hirakawa et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2018)
Expanded autologous regulatory T-lymphocyte infusions in ALS A phase I, first-in-human study
Jason R. Thonhoff et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Drug repurposing from the perspective of pharmaceutical companies
Y. Cha et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis
Ricarda A. L. Menke et al.
NEUROTHERAPEUTICS (2017)
Drugs in clinical development for the treatment of amyotrophic lateral sclerosis
Ana Martinez et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Genetic screening in sporadic ALS and FTD
Martin R. Turner et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance
Mamede de Carvalho et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Cortical influences drive amyotrophic lateral sclerosis
Andrew Eisen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
Koji Abe et al.
LANCET NEUROLOGY (2017)
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials
Ruben P. A. van Eijk et al.
NEUROLOGY (2017)
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial
Richard Smith et al.
NEUROTHERAPEUTICS (2017)
Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis
Tania F. Gendron et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Comparison of the King's and MiToS staging systems for ALS
Ton Fang et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2017)
July 2017 ENCALS statement on edaravone
Ammar Al-Chalabi et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2017)
Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis
Margaret O'Brien et al.
JAMA NEUROLOGY (2017)
Blood Biomarkers of Carbohydrate, Lipid, and Apolipoprotein Metabolisms and Risk of Amyotrophic Lateral Sclerosis: A More Than 20-Year Follow-up of the Swedish AMORIS Cohort
Daniela Mariosa et al.
ANNALS OF NEUROLOGY (2017)
Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis
Mahtab Ghadiri et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Clinical trials from the patient perspective: survey in an online patient community
Pronabesh DasMahapatra et al.
BMC HEALTH SERVICES RESEARCH (2017)
Rate of disease progression: a prognostic biomarker in ALS
Julie Labra et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
How common are ALS plateaus and reversals?
Richard S. Bedlack et al.
NEUROLOGY (2016)
Assessment of the upper motor neuron in amyotrophic lateral sclerosis
William Huynh et al.
CLINICAL NEUROPHYSIOLOGY (2016)
Efficiencies of platform clinical trials: A vision of the future
Benjamin R. Saville et al.
CLINICAL TRIALS (2016)
New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel
Leslie A. Rudzinski et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2016)
Neuronal network disintegration: common pathways linking neurodegenerative diseases
Rebekah M. Ahmed et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Amyotrophic lateral sclerosis: moving towards a new classification system
Ammar Al-Chalabi et al.
LANCET NEUROLOGY (2016)
Pathophysiological and diagnostic implications of cortical dysfunction in ALS
Nimeshan Geevasinga et al.
NATURE REVIEWS NEUROLOGY (2016)
Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience
Jerome Mertens et al.
NATURE REVIEWS NEUROSCIENCE (2016)
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression
Michael D. Weiss et al.
NEUROLOGY (2016)
Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS
Nimeshan Geevasinga et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2016)
TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes
Rachel H. Tan et al.
BRAIN (2015)
The MITOS system predicts long-term survival in amyotrophic lateral sclerosis
Irene Tramacere et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study (vol 14, pg 478, 2015)
P. Menon et al.
LANCET NEUROLOGY (2015)
Neurofilament light chain A prognostic biomarker in amyotrophic lateral sclerosis
Ching-Hua Lu et al.
NEUROLOGY (2015)
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?
Katharine A. Nicholson et al.
NEUROTHERAPEUTICS (2015)
Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis
Seward B. Rutkove
NEUROTHERAPEUTICS (2015)
A multi-center screening trial of rasagiline in patients with amyotrophic lateral
Zachary Macchi et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2015)
Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial
Susanna B. Park et al.
EBIOMEDICINE (2015)
Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials
Rubika Balendra et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study
Parvathi Menon et al.
LANCET NEUROLOGY (2015)
Quantifying Disease Progression in Amyotrophic Lateral Sclerosis
Neil G. Simon et al.
ANNALS OF NEUROLOGY (2014)
Amyotrophic lateral sclerosis: a long preclinical period?
Andrew Eisen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial
Merit E. Cudkowicz et al.
LANCET NEUROLOGY (2014)
Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders
Lindsay C. Burrage et al.
MOLECULAR GENETICS AND METABOLISM (2014)
The PRO-ACT database Design, initial analyses, and predictive features
Nazem Atassi et al.
NEUROLOGY (2014)
Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies
Steve Vucic et al.
TRENDS IN NEUROSCIENCES (2014)
Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons
Brian J. Wainger et al.
CELL REPORTS (2014)
ALSUntangled No. 26: Lunasin The ALSUntangled Group
Richard Bedlack et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2014)
A High-Content Screen Identifies Novel Compounds That Inhibit Stress-Induced TDP-43 Cellular Aggregation and Associated Cytotoxicity
Justin D. Boyd et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Aggregation of Neurologic and Neuropsychiatric Disease in Amyotrophic Lateral Sclerosis Kindreds: A Population-Based Case-Control Cohort Study of Familial and Sporadic Amyotrophic Lateral Sclerosis
Susan Byrne et al.
ANNALS OF NEUROLOGY (2013)
Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis
Steve Vucic et al.
BRAIN (2013)
S[ plus ] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis
Richard J. Mead et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Pathophysiological insights into ALS with C9ORF72 expansions
Kelly L. Williams et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)
T. M. Miller et al.
LANCET NEUROLOGY (2013)
Controversies and priorities in amyotrophic lateral sclerosis
Martin R. Turner et al.
LANCET NEUROLOGY (2013)
The epidemiology of ALS: a conspiracy of genes, environment and time
Ammar Al-Chalabi et al.
NATURE REVIEWS NEUROLOGY (2013)
Analysis of start-up, retention, and adherence in ALS clinical trials
Nazem Atassi et al.
NEUROLOGY (2013)
Alzheimer disease in the United States (2010-2050) estimated using the 2010 census
Liesi E. Hebert et al.
NEUROLOGY (2013)
RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
Christopher J. Donnelly et al.
NEURON (2013)
Monetary Costs of Dementia in the United States
Michael D. Hurd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Timothy M. Miller et al.
LANCET NEUROLOGY (2013)
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
Laura Obici et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2012)
Online assessment of ALS functional rating scale compares well to in-clinic evaluation: A prospective trial
Andre Maier et al.
AMYOTROPHIC LATERAL SCLEROSIS (2012)
Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis
Radhia Benmohamed et al.
AMYOTROPHIC LATERAL SCLEROSIS (2011)
Amyotrophic lateral sclerosis
Matthew C. Kiernan et al.
LANCET (2011)
Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm
Paul Wicks et al.
NATURE BIOTECHNOLOGY (2011)
Clinical diagnosis and management of amyotrophic lateral sclerosis
Orla Hardiman et al.
NATURE REVIEWS NEUROLOGY (2011)
Family history of neurodegenerative and vascular diseases in ALS A population-based study
M. H. B. Huisman et al.
NEUROLOGY (2011)
A pilot trial of memantine and riluzole in ALS: Correlation to CSF biomarkers
Todd D. Levine et al.
AMYOTROPHIC LATERAL SCLEROSIS (2010)
A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis
Mamede De Carvalho et al.
AMYOTROPHIC LATERAL SCLEROSIS (2010)
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis
Ian P. Blair et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Phase 2 study of sodium phenylbutyrate in ALS
Merit E. Cudkowicz et al.
AMYOTROPHIC LATERAL SCLEROSIS (2009)
Arimoclomol: a potential therapy under development for ALS
Veena Lanka et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Biomarkers in amyotrophic lateral sclerosis
Martin R. Turner et al.
LANCET NEUROLOGY (2009)
Scrutinizing enrollment in ALS clinical trials: Room for improvement?
Richard S. Bedlack et al.
AMYOTROPHIC LATERAL SCLEROSIS (2008)
ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1
Hideki Nishitoh et al.
GENES & DEVELOPMENT (2008)
Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis
Merit E. Cudkowicz et al.
MUSCLE & NERVE (2008)
Induction of pluripotent stem cells from adult human fibroblasts by defined factors
Kazutoshi Takahashi et al.
CELL (2007)
Interleukin-2 receptor signaling in regulatory T cell development and homeostasis
Matthew A. Burchill et al.
IMMUNOLOGY LETTERS (2007)
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Manuela Neumann et al.
SCIENCE (2006)
Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
M de Carvalho et al.
ARCHIVES OF NEUROLOGY (2006)
Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury
Hiroshi Yoshida et al.
CNS DRUG REVIEWS (2006)
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model
S Waibel et al.
JOURNAL OF NEUROLOGY (2004)
Improving efficiency of ALS clinical trials using lead-in designs
DH Moore et al.
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS (2004)
Multi-drug therapy in amyotrophic lateral sclerosis - The case for a multi-drug approach
J Rosenfeld
MUSCLE & NERVE (2004)
Share Paper
